Match!
M. Hidalgo
Cornell University
CancerPathologyOncologyImmunologyAdjuvant therapyPembrolizumabPancreatic cancerGemcitabineIrinotecanCancer researchClinical trialMedicine
46Publications
7H-index
197Citations
What is this?
Publications 16
Newest
Last. Ling Huang (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 5
view all 15 authors...
Metastasis development is the leading cause of cancer-related mortality in pancreatic ductal adenocarcinoma (PDAC) and yet, few preclinical systems to recapitulate its full spreading process are available. Thus, modeling of tumor progression to metastasis is urgently needed. In this work, we describe the generation of highly metastatic PDAC patient-derived xenograft (PDX) mouse models and subsequent single-cell RNA sequencing of circulating tumor cells (CTC), isolated by human HLA sorting, to id...
Source
#1Bruno Bockorny (Harvard University)H-Index: 9
#2Valerya Semenisty (Rambam Health Care Campus)
Last. Katrina S. Pedersen (WashU: Washington University in St. Louis)H-Index: 5
view all 26 authors...
Programmed cell death 1 (PD-1) inhibitors have limited effect in pancreatic ductal adenocarcinoma (PDAC), underscoring the need to co-target alternative pathways. CXC chemokine receptor 4 (CXCR4) blockade promotes T cell tumor infiltration and is synergistic with anti-PD-1 therapy in PDAC mouse models. We conducted a phase IIa, open-label, two-cohort study to assess the safety, efficacy and immunobiological effects of the CXCR4 antagonist BL-8040 (motixafortide) with pembrolizumab and chemothera...
Source
Last. David J. Shields (Pfizer)H-Index: 5
view all 12 authors...
Summary Inhibition of the cell-cycle kinases CDK4 and CDK6 is now part of the standard treatment in advanced breast cancer. CDK4/6 inhibitors, however, are not expected to cooperate with DNA-damaging or antimitotic chemotherapies as the former prevent cell-cycle entry, thus interfering with S-phase- or mitosis-targeting agents. Here, we report that sequential administration of CDK4/6 inhibitors after taxanes cooperates to prevent cellular proliferation in pancreatic ductal adenocarcinoma (PDAC) ...
7 CitationsSource
#1Madappa N. Kundranda (University of Texas MD Anderson Cancer Center)H-Index: 6
#2David Propper (St Bartholomew's Hospital)H-Index: 25
Last. Leonardo O. RodriguesH-Index: 2
view all 16 authors...
723Background: BPM31510-IV is an Ubidecarenone (CoQ10) drug-lipid conjugate nanodispersion targeting metabolic machinery in cancer, shifting bioenergetics from lactate dependency towards mitochondr...
Source
#1Christopher Duane Nevala-Plagemann (UofU: University of Utah)H-Index: 2
#2M. Hidalgo (Cornell University)H-Index: 7
Last. Ignacio Garrido-Laguna (UofU: University of Utah)H-Index: 21
view all 3 authors...
Improvements in the outcomes of patients with pancreatic ductal adenocarcinoma (PDAC) have lagged behind advances made in the treatment of many other malignancies over the past few decades. For most patients with PDAC, cytotoxic chemotherapy remains the mainstay of treatment. For patients with resectable disease, modified 5-fluorouracil, leucovorin, irinotecan and oxaliplatin (mFOLFIRINOX) is the standard-of-care adjuvant therapy, although data from several randomized trials have shown improved ...
11 CitationsSource
#1Pascal HammelH-Index: 63
#2Rosanna Berardi (Marche Polytechnic University)H-Index: 1
Last. M. Hidalgo (Cornell University)H-Index: 7
view all 19 authors...
Background: Second-line treatment options for advanced pancreatic adenocarcinoma are currently limited. Eryaspase, asparaginase (ASNase) encapsulated in red blood cells (RBCs), is an investigational product under development. Following infusion, asparagine and glutamine are actively transported into RBCs where they are hydrolyzed by the encapsulated ASNase. We have recently reported the outcome of a randomized phase 2b study in patients with advanced pancreatic cancer whose disease progressed fo...
Source
#1M. Hidalgo (Cornell University)H-Index: 7
#1M. Hidalgo (Cornell University)H-Index: 1
Last. Teresa MacarullaH-Index: 29
view all 16 authors...
Abstract Background Current treatment options for PDAC are limited. While PD-1/PD-L1 antagonists have shown promising results in other cancer types, this approach has been ineffective in PDAC. In Cohort 1 of the COMBAT study, the dual combination of BL-8040 (a CXCR4 inhibitor) and Pembrolizumab was safe and showed a promising 7.5 mo OS in 2L patients. BL-8040 modified the TME by promoting infiltration of effector T cells and decreasing immune suppressor cells. Based on these encouraging results,...
4 CitationsSource
#5Beatriz SalvadorH-Index: 13
Last. Manuel HidalgoH-Index: 80
view all 8 authors...
Source
11074 Background: Treatment options for patients (pts) with colorectal cancer (CRC) have increased in the last years. However, there are no validated prospective molecular markers in CRC to select which agents are better to treat any individual case. The aim of this study was to determine the feasibility of developing an implementing a biomarker panel to guide treatment selection in this setting. Methods: Colorectal cancer tumors were prospectively analyzed with a predefined set of 11 molecular ...
#1J. W. Goldman (UCLA Medical Center)H-Index: 2
#1Jonathan W. GoldmanH-Index: 31
Last. Lee S. Rosen (UCLA Medical Center)H-Index: 43
view all 10 authors...
ABSTRACT Background Dysregulation of the Hh pathway is a principal event in the carcinogenesis of multiple tumor types, including basal cell carcinoma. TAK-441 is an investigational, orally-available inhibitor of the G protein-coupled receptor Smoothened, a component of the Hh signalling cascade. Methods This study (NCT01204073) was designed to determine safety, maximum tolerated dose (MTD) and maximum feasible dose (MFD) in patients with advanced solid tumors. Cycles consisted of 3 weeks contin...
2 CitationsSource
12